Incyte Hopes To Augment Immune/Inflammation Pipeline With Escient Deal

 
• By Joseph Haas
  
Incyte looks to address coming patent cliff by buying Escient
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business